RemoteA’s SmartECG Platform is now CE certified and ready to accelerate the diagnosis of heart patients

Thu, 04/11/2019 - 09:01

After several years of development, RemoteA’s SmartECG Platform has now been completed and granted CE mark for Class IIa medical device software. The SmartECG Platform is a new way of analyzing long-term ECG data, speeding up the diagnosis of heart patients and access to treatment. The platform combines a top quality automatic analysis with an easy-to-use browser user interface. The analysis algorithm is based on RemoteA’s database with 1.5 million hours of cardiac data and 90,000 cardiologists’ consultations. The SmartECG Platform improves resource efficiency in healthcare:  analysis time can be reduced significantly and more patients can be monitored with less costs. All this will result in better patient experience. The project is co-funded by the H2020 programme of the European Union.

The SmartECG Platform  is s a new way of viewing and analyzing long-term ECG data from ambulatory ECG (Holter) devices. It is a clinical decision support tool that facilitates the diagnosis of cardiac disorders. The platform consists of a top quality automatic analysis and an easy-to-use browser user interface. The physician receives an automatic analysis in a few  minutes after uploading an ECG recording to the Platform. The analysis algorithm draws on 1.5 million hours of cardiac data from a total of more than 90,000 patients.

“The foundation for SmartECG is our extensive experience in remote diagnostics services and our comprehensive algorithm expertise. Large amounts of data, more advanced algorithms, and higher computing capacity enable us to create better tools to support physicians in their decision-making,” says Kimmo Suotsalo, RemoteA’s Chief Technology Officer.

The CE certification process is now completed and the product meets the requirements of the Medical Device Directive 93/42/EEC. The SmartECG Platform provides several advantages. Long-term ECG data analysis time can be reduced significantly. Average cost of analyzing long-term ECG data will decrease as less patients need to be referred to secondary care. For patients, better monitoring resources in the primary care mean less hassle and better patient experience, especially when the tests prove negative.

Further information:
Kimmo Suotsalo, Chief Technology Officer, RemoteA Ltd, tel. +358 45 239 7297, kimmo.suotsalo(at)

RemoteA Ltd is a privately owned Finnish medical technology company founded in 2002, specializing in cardiac data analysis and electronic healthcare services. As pioneers in remote diagnostics, we have provided healthcare units in Finland, Sweden and the UK with a total of 170,000 ECG, sleep apnea and blood pressure remote analyses in the past fifteen years. We employ software, algorithm and business experts and cooperate with leading cardiologists.